MEDICAL POLICY

Vagus Nerve Stimulation
(All Lines of Business Except Medicare)

Effective Date: 1/1/2020

Section: SUR
Policy No: 363

Technology Assessment Committee Approved Date: 6/16
Medical Policy Committee Approved Date: 8/17; 2/18; 4/18; 12/18

1/1/2020
Medical Officer

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

SCOPE:

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

APPLIES TO:

All lines of business except Medicare

BENEFIT APPLICATION

Medicaid Members

Oregon: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

POLICY CRITERIA

I. Implantable vagus nerve stimulation may be considered medically necessary and covered as a treatment of partial onset (focal) seizures when all of the following criteria (A.-C.) are met:

   A. Seizures are refractory to ≥ 2 antiepileptic drugs (AEDs) or AEDs are contraindicated; and

   B. Surgery has failed or patient is not a surgical candidate; and

   C. Left or bilateral vagotomy has not been performed.

II. Revision or removal of a vagus nerve stimulation device may be considered medically necessary and covered when any of the following (A.-C.) criteria are met:
A. Documented complications related to the device placement; or
B. Replacement is for the end of the useful life of the device; or
C. Replacement is due to a device malfunction.

III. Vagus nerve stimulation is considered investigational and not covered when criteria I. or II. above are not met, including, but not limited to any of the following:

A. Non-invasive/non-implantable vagus nerve stimulation devices
B. Percutaneous and transcutaneous vagus nerve stimulation devices
C. Vagus nerve stimulation devices such as the AspireSR generator that add additional automatic stimulation utilizing an individualized cardiac-based algorithm
D. Indications other than partial onset seizures, including but not limited to:
   • Refractory depression
   • Alzheimer’s disease
   • Obesity
   • Migraine headaches
   • Essential tremor
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>64570</td>
<td>Removal of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator</td>
</tr>
<tr>
<td>C1767</td>
<td>Generator, neurostimulator (implantable), non-rechargeable</td>
</tr>
<tr>
<td>C1778</td>
<td>Lead, neurostimulator (implantable)</td>
</tr>
<tr>
<td>C1816</td>
<td>Receiver and/or transmitter, neurostimulator (implantable)</td>
</tr>
<tr>
<td>C1820</td>
<td>Generator, neurostimulator (implantable), with rechargeable battery and charging system</td>
</tr>
<tr>
<td>C1823</td>
<td>Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads</td>
</tr>
<tr>
<td>C1883</td>
<td>Adapter/extension, pacing lead or neurostimulator lead (implantable)</td>
</tr>
<tr>
<td>L8679</td>
<td>Implantable neurostimulator, pulse generator, any type</td>
</tr>
<tr>
<td>L8680</td>
<td>Implantable neurostimulator electrode, each</td>
</tr>
<tr>
<td>L8681</td>
<td>Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only</td>
</tr>
<tr>
<td>L8682</td>
<td>Implantable neurostimulator radiofrequency receiver</td>
</tr>
<tr>
<td>L8683</td>
<td>Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver</td>
</tr>
<tr>
<td>L8685</td>
<td>Implantable neurostimulator pulse generator, single array, rechargeable, includes extension</td>
</tr>
<tr>
<td>L8686</td>
<td>Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension</td>
</tr>
<tr>
<td>L8687</td>
<td>Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension</td>
</tr>
<tr>
<td>L8688</td>
<td>Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension</td>
</tr>
<tr>
<td>L8689</td>
<td>External recharging system for battery (internal) for use with implantable neurostimulator, replacement only</td>
</tr>
</tbody>
</table>

**No Prior Authorization Required**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>95970</td>
<td>Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple or complex brain, spinal cord, or peripheral (ie, cranial nerve, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, without reprogramming</td>
</tr>
<tr>
<td>95974</td>
<td>Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour</td>
</tr>
<tr>
<td>95975</td>
<td>Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour</td>
</tr>
</tbody>
</table>

**MEDICAL POLICY**

**Vagus Nerve Stimulation**

(All Lines of Business Except Medicare)
DESCRIPTION

Epilepsy

Epilepsy is a neurological disorder that causes recurrent and unprovoked seizures. Although epilepsy can
develop in people of all ages, it is most common in children in the elderly. The cause of epilepsy varies
and may be due to structural abnormalities, abnormal brain development, traumatic brain injury, or
brain tumors. Use of a single antiepileptic drugs (AEDs) is the first-line therapy for epilepsy, however, up
to 20-30% of these patients may develop drug-resistant (i.e., drug-refractory) epilepsy. The International
League Against Epilepsy defines drug-refractory epilepsy as “a failure of adequate trials of 2 tolerated
and appropriately chosen and used AED schedules.” Some drug-refractory epilepsy patients may be
surgical candidates. However, “not all patients with drug-resistant epilepsy can undergo surgery and
some patients continue to experience seizures following surgery.” Vagus nerve stimulation is an option
for these AED-refractory patients who are not surgical candidates. The Food & Drug Administration
(FDA)-approved Vagal Nerve Stimulation (VNS) Therapy System™ (Cyberonics Inc.) is indicated for
patients with partial onset seizures. A partial onset seizure starts in one area of the brain and may or
may not result in a loss of motor control and consciousness. These are the most common types of
seizures in people with epilepsy.

Vagus Nerve Stimulation (VNS)

Implantable

A VNS device consists of a programmable generator, wire leads, and electrodes. The generator is
implanted subcutaneously into the patient’s chest. The generator then delivers periodic pulses of
electrical current through the leads to the electrodes, which are attached to the vagus nerve in the left
side of the neck. The frequency and intensity of the electrical pulses is adjusted for each patient’s needs.

Percutaneous, Transcutaneous, and Non-invasive/Non-implantable

Percutaneous vagus nerve stimulation (pVNS) and transcutaneous vagus nerve stimulation (tVNS) are
proposed as minimally invasive and methods to modulate vagal nerve activity via electrical signal. In a
similar manner, non-invasive or non-implantable (nVNS) devices deliver electrical pulses by attachment
to the skin (e.g., by earlobe clip or through the side of the neck).
REVIEW OF EVIDENCE

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of vagus nerve stimulation as a treatment for seizures and other purported indications. Below is a summary of the available evidence identified through December of 2019.

Implantable Vagus Nerve Stimulation

Medically Refractory Seizures

Panebianco and colleagues published an updated Cochrane review in 2015, regarding the efficacy and tolerability of vagus nerve stimulation as an adjunctive therapy for treating people with medically refractory partial epilepsy.\(^3\) Five trials were included in the analyses, totalling 439 participants, of which four were included in meta-analyses: Handforth et al. (1998), Michael (1993), The Vagus Nerve Stimulation Study Group (1995), and Klinkenberg et al (2012).\(^4\)–\(^7\) Amongst the five studies, two were rated as low risk of bias, and three as unclear. Effective blinding for VNS is difficult given the associated effects during use (e.g., voice alteration). The authors noted this may alter the validity of effects observed. Overall, the review concluded that VNS for partial seizures appeared to be effective and well tolerated in the 439 patients studied.

Depression

In 2013 (updated 2017), Hayes conducted an evidence review to evaluate vagus nerve stimulation for the treatment of depression.\(^8\) The review identified 11 clinical studies and 2 meta-analyses with sample sizes ranging from 18 to 636 patients with treatment-resistant major depression disorder (MDD) or bipolar disorder. The longest follow-up times ranged from 1 to 2 years. The outcomes of interest included changes in depression severity, quality of life (QOL), changes in medication and therapies for depression, suicide rates and rates for suicide ideation, and complications.

Overall, VNS was associated with ≥ 50% reduction in depression severity scores (Hamilton Depression Rating Scale [HDRS]) in 15% to 50% of patients within the first year, 27% to 55% at 1 year, and 42% to 53% at 2 years. “However, while a ≥ 50% improvement of HDRS baseline scores is generally considered clinically significant, patients with high scores at baseline could still have moderate to severe depression, even after ≥ 50% improvement in scores. Therefore, it is possible that, despite a 50% improvement, the patient still suffers from severe depression. Furthermore, in the only randomized controlled trial (RCT), active VNS with an implantable device (n=112) was no more effective than sham VNS (n=110) in alleviating symptoms of depression.”\(^8\) Based on the evidence from 2 studies there was insufficient evidence to determine if VNS therapy reduces medication use and therapies for depression. The results of 2 studies indicated that VNS therapy does not decrease suicide rates in patients with severe depression. There was insufficient data to thoroughly evaluate complications related to VNS therapy for depression.

The overall quality of evidence was determined to be of low quality. There was only 1 randomized controlled trial, 5 nonrandomized controlled studies, and 5 uncontrolled studies. Additionally, most
studies were funded by the device manufacturer and had significant design limitations. Ultimately, Hayes gave the following ratings for the use of VNS to treat refractory major depression disorder:

- **C** – For VNS as an adjunctive treatment for adults with severe major depression or bipolar disorder I and II when symptoms associated with a major depressive episode are refractory to multiple regimens of noninvasive treatments such as medication, psychotherapy, and electroconvulsive therapy. Patients should be free of comorbidities that could increase the risk of VNS. This Rating is based on the positive reports from nonrandomized and noncontrolled studies, the lack of evidence from randomized studies, the lack of thorough safety data regarding the device, and the substantial burden of treatment-resistant depression. Considering the safety concerns regarding VNS, noninvasive treatments should be exhausted before this option is considered, and patients should be specifically informed of the risks and properly followed up.

- **D2** – For VNS for adults with severe major depression or bipolar disorder I and II when noninvasive treatments have not been exhausted. This Rating is based on the negative results from 1 RCT, which contrasts with the positive reports from nonrandomized and noncontrolled studies; the lack of thorough safety data regarding the device; and the available alternative treatment options.

- **D2** – For VNS for adults with severe, treatment-resistant rapid cycling bipolar disorder. This Rating reflects the limited evidence available for this patient population.

**Other Indications**

The evidence review identified studies evaluating other purported indications for VNS therapy, including:

- Alzheimer’s disease\(^9\, ^{10}\)
- Migraine headaches\(^11\, ^{14}\)
- Essential tremor\(^15\)

**Non-invasive/Non-implantable Vagus Nerve Stimulation**

The only non-implantable VNS (nVNS) device with U.S. Food and Drug Administration (FDA) clearance is gammaCore™ (electroCore, Inc.), which is indicated for adjunctive use for the preventive treatment of cluster headache and for the acute treatment of pain associated with episodic cluster headache and migraine headache in adult patients.\(^16\) As such, this evidence summary will focuses solely on the gammaCore™ device, and approved indications.

**Cluster Headache**

The ACT1 and ACT2 trials were reported out by Silberstein et al. and Goadsby et al. in 2016 and 2018, respectively.\(^17\, ^{18}\) Both of the manufacturer-sponsored randomized trials were double-blind and sham-controlled evaluations of the gammaCore nVNS device.
ACT1 (N=150) included 1 month of treatment comparison, followed by a 3-month open-label phase. Participants used the device following their first cluster headache attack, and use of rescue medication within 60 minutes was considered treatment failure. All endpoints were assessed by patient-recorded diaries, the primary end-point being the proportion of all subjects who achieved a pain intensity score of 0 or 1 on a 5-point scale (0, no pain; 4, very severe pain) at 15 minutes after treatment initiation. During the first month, 22 participants dropped out (nVNS, N=14; sham, N=8); a large proportion of participants guessed their treatment allocation beyond chance. In the second phase, 28 participants dropped out (nVNS, N=17; sham, N=11). For the analysis, 133 subjects met the criteria for intention-to-treat (nVNS, N=60; sham, N=73). The participants had originally been split into two distinct cohorts – one for episodic cluster headaches (eCH), and one for chronic cluster headaches (cCH). Response rates were significantly higher with nVNS than with sham for the eCH cohort (nVNS, 34.2%; sham,10.6%; p =0.008) but not the cCH cohort (nVNS, 13.6%; sham, 23.1%; p = 0.48). In the total population, a significant difference in response rates between the nVNS and sham groups was not observed.

ACT2 enrolled 102 subjects (nVNS, N=50; sham, N=52) for a 2-week, randomized, double-blind period; and a 2-week, open-label period wherein all subjects received nVNS therapy. Overall, the authors concluded that nVNS was superior to sham therapy for acute treatment of attacks in patients with eCH but not those with cCH or in the total population. This finding was in alignment with the ACT1 study.

These studies represent short-term early conclusions that nVNS may be beneficial to patients with eCH, though not cCH, but more research is needed to know for sure.

Migraine

In 2018, three publications reported on the double-blind, sham-controlled nVNS trial, PRESTO. The primary results, and both post-hoc analyses were funded by the manufacturer, electroCore, Inc. Authors of all three papers disclosed receiving electroCore consultancy fees, being electroCore employees, and receiving electroCore stock ownership. PRESTO aimed to evaluate the efficacy, safety, and tolerability of gammaCore (nVNS) for the acute treatment of migraine. Two hundred and forty-eight participants with episodic migraine with/without aura were randomized to receive nVNS (N=122) or sham (N=126) within 20 minutes from pain onset. Participants were to repeat treatment if pain had not improved in 15 minutes. The double-blind study period lasted 4 weeks or until patients had treated 5 attacks. An open-label period subsequently followed, lasting 4 weeks or 5 attacks. There was no statistically significant difference in the primary endpoint: the proportion of participants who were pain-free without using rescue medication at 120 minutes following therapy (30.4% [nVNS] vs 19.7% [sham], p=.067), though nVNS was superior to sham for freedom from pain at 30 (12.7% vs 4.2%; p = 0.012) and 60 minutes (21.0% vs 10.0%; p = 0.023). Adverse events in PRESTO (nVNS = 22, sham = 23) were most commonly application site discomfort and nasopharyngitis. Given these reports all demonstrate marginally or non-statistically significant superior nVNS outcomes as a results of a single trial, additional well-designed RCT’s are needed to determine overall health outcomes.
The evidence review identified 4 studies evaluating VNS that adds additional automatic stimulation utilizing an individualized cardiac-based algorithm (i.e., AspireSR VNS). Due to methodological limitations (lack of randomized controlled design, small sample sizes, lack of statistical analyses, and short follow-up periods), these studies provide insufficient evidence to support the safety and clinical utility of this device compared to the standard VNS device. Additional good-quality studies are needed to demonstrate that VNS with automatic stimulation based on an individual’s cardiac rhythm improves health outcomes in patients with refractory epilepsy.

**CLINICAL PRACTICE GUIDELINES**

**Seizures**

American Academy of Neurology (AAN)

The 2013 AAN evidence-based clinical practice guideline for vagus nerve stimulation as adjunctive therapy for partial-onset seizures in patients >12 years gave the following recommendations:

- VNS may be considered as adjunctive treatment for children with partial or generalized epilepsy (Level C).
- VNS may be considered in patients with Lennox-Gastaut Syndrome (LGS) (Level C).
- In adult patients receiving VNS for epilepsy, improvement in mood may be an additional benefit (Level C).
- VNS may be considered progressively effective in patients over multiple years of exposure (Level C).
- Optimal VNS settings are still unknown, and the evidence is insufficient to support a recommendation for the use of standard stimulation vs. rapid stimulation to reduce seizure occurrence (Level U).
- Patients may be counseled that VNS magnet activation may be associated with seizure abortion when used at the time of seizure auras (Level C) and that seizure abortion with magnet use may be associated with overall response to VNS treatment (Level C).

National Institute for Health and Care Excellence (NICE)

For epilepsy diagnosis and management, a 2019-updated NICE guideline states, “Vagus nerve stimulation is indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults who are refractory to antiepileptic medication but who are not suitable for resective surgery. This includes adults whose epileptic disorder is dominated by focal seizures (with or without secondary generalisation) or generalised seizures.” The same statement is made for children.
Vagus Nerve Stimulation
(All Lines of Business Except Medicare)

Depression

Department of Veterans Affairs/Department of Defense (VA/DoD)

The 2016 evidence-based VA/DoD clinical practice guideline for the management of major depressive disorder (MDD) recommended “against offering vagus nerve stimulation (VNS) for patients with MDD, including patients with severe treatment-resistant depression outside of a research setting.”

National Institute for Health and Care Excellence (NICE)

The 2009 evidence-based NICE guideline for vagus nerve stimulation for treatment-resistant depression stated, “current evidence on the safety and efficacy of vagus nerve stimulation (VNS) for treatment-resistant depression is inadequate in quantity and quality. Therefore this procedure should be used only with special arrangements for clinical governance, consent and audit or research.”

POLICY SUMMARY

There is sufficient evidence to establish the efficacy and safety of implantable vagus nerve stimulation (VNS) for medically-refractory epilepsy. Additionally, the American Academy of Neurology and National Institute for Health and Care Excellence recommend VNS in medically-refractory epilepsy patients.

There is insufficient evidence to establish the efficacy and safety of implantable VNS for any other indication, including, but not limited to Alzheimer’s disease, migraine headaches, or essential tremor. There is a paucity of compelling evidence for non-implantable, percutaneous, and transcutaneous VNS devices as well. All identified studies had significant methodological limitations, including, lack of randomized controlled design, small sample sizes, lack of comparator group, and short follow-up periods. For implantable VNS therapy, FDA-approval does not exist for these additional indications. For non-implantable, percutaneous, and transcutaneous VNS therapy, additional research is still needed to draw conclusions about the overall health outcomes. Additional good-quality studies and expanded FDA-approval are required to support the medical necessity of VNS therapy for these indications and device types.

INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days notice of policy changes that are restrictive in nature.
The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

**REGULATORY STATUS**

**U.S. Food and Drug Administration (FDA)**

**Implantable VNS**

Numerous implantable stimulator systems marketed by Cyberonics, Inc have gained premarket approval from the FDA, though the approval orders link back to the original 1997 issuance. FDA Product Codes: MUZ and LYZ.

<table>
<thead>
<tr>
<th>Product and Manufacturer</th>
<th>Indications for Use</th>
<th>Contraindications for Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>The VNS Therapy™ System by Cyberonics Inc.</td>
<td>The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.</td>
<td>Vagotomy—The VNS Therapy System cannot be used in patients after a bilateral or left cervical vagotomy. Diathermy—Do not use shortwave diathermy, microwave diathermy, or therapeutic ultrasound diathermy (hereafter referred to as diathermy) on patients implanted with a VNS Therapy System. Diagnostic ultrasound is not included in this contraindication.</td>
</tr>
</tbody>
</table>

Prior to June of 2017, the FDA indications for the VNS Therapy System™ were for patients 12 years of age and older.

**Non-implantable VNS**

electroCore, LLC markets a non-invasive VNS (gammaCore™), indicated for treatment of cluster headache. The intent is to reduce the frequency of cluster headache attacks. The device received approval in 2017 and is intended for non-invasive vagus nerve stimulation on the side of the neck. Product code: PKR

**Percutaneous and Transcutaneous Vagus Nerve Stimulation**

The Parasymp Device has been given an Investigational Device Exception for several indications currently under investigation for research use only. The device is not approved for purchase in the United States.
Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case.

REFERENCES

<table>
<thead>
<tr>
<th>Medical Policy</th>
<th>Vagus Nerve Stimulation (All Lines of Business Except Medicare)</th>
</tr>
</thead>
</table>


